Search Results - "Claggett, B L"

Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure by Simpson, Joanne, Jhund, Pardeep S, Lund, Lars H, Padmanabhan, Sandosh, Claggett, Brian L, Shen, Li, Petrie, Mark C, Abraham, William T, Desai, Akshay S, Dickstein, Kenneth, Køber, Lars, Packer, Milton, Rouleau, Jean L, Mueller-Velten, Guenther, Solomon, Scott D, Swedberg, Karl, Zile, Michael R, McMurray, John J V

“…Accurate prediction of risk of death or hospitalizations in patients with heart failure (HF) may allow physicians to explore how more accurate decisions…”
Get more information

Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis by Rohde, Luis E., Claggett, Brian L., Wolsk, Emil, Packer, Milton, Zile, Michael, Swedberg, Karl, Rouleau, Jean, Pfeffer, Marc A., Desai, Akshay S., Lund, Lars H., Kober, Lars, Anand, Inder, Merkely, Bela, Senni, Michele, Shi, Victor, Rizkala, Adel, Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D.

“…The net clinical benefit of cardiac disease-modifying drugs might be influenced by the interaction of different domains of disease burden. We assessed the…”
Get full text

Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure by Zile, Michael R., MD, Claggett, Brian L., PhD, Prescott, Margaret F., PhD, McMurray, John J.V., MD, Packer, Milton, MD, Rouleau, Jean L., MD, Swedberg, Karl, MD, Desai, Akshay S., MD, Gong, Jianjian, PhD, Shi, Victor C., MD, Solomon, Scott D., MD

“…Abstract Background Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance of changes in NP from baseline is…”
Get full text

Declining Risk of Sudden Death in Heart Failure by Shen, Li, Jhund, Pardeep S, Petrie, Mark C, Claggett, Brian L, Barlera, Simona, Cleland, John G.F, Dargie, Henry J, Granger, Christopher B, Kjekshus, John, Køber, Lars, Latini, Roberto, Maggioni, Aldo P, Packer, Milton, Pitt, Bertram, Solomon, Scott D, Swedberg, Karl, Tavazzi, Luigi, Wikstrand, John, Zannad, Faiez, Zile, Michael R, McMurray, John J.V

“…Data were analyzed from 40,195 patients with heart failure with reduced ejection fraction enrolled in 12 clinical trials in the 1995–2014 period. Sudden-death…”
Get full text

Relative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against hospitalizations and mortality according to frailty score: a post-hoc analysis of the DANFLU-1 trial by Espersen, C, Johansen, N D, Modin, D, Janstrup, K H, Nealon, J, Samson, S, Salamand, C, Loiacono, M M, Jensen, A M R, Landler, N E, Claggett, B L, Solomon, S, Gislason, G H, Koeber, L, Biering-Soerensen, T

“…Abstract Background Frailty is a major risk factor for adverse cardiovascular events. Influenza vaccination has been shown to protect against cardiovascular…”
Get full text

Electronic nudges to increase influenza vaccination in patients with chronic kidney disease: a prespecified analysis of NUDGE-FLU-CHRONIC by Grundtvig Skaarup, K G, Johansen, N D, Vaduganathan, M, Bhatt, A, Modin, D, Chatur, S, Claggett, B L, Janstrup, K H, Kober, L, Solomon, S D, Sivapalan, P, Jensen, J U S, Martel, C, Krause, T G, Biering-Sorensen, T

“…Abstract Background Annual influenza vaccination is recommended for individuals with chronic kidney disease (CKD); however, guideline adherence is suboptimal…”
Get full text

Race in heart failure: a pooled participant-level analysis of the global PARADIGM-HF and PARAGON-HF trials by Lu, H, Claggett, B L, Packer, M, Pfeffer, M A, Lewis, E F, Lam, C S P, Swedberg, K, Rouleau, J, Zile, M R, Lefkowitz, M, Desai, A S, Jhund, P, Mcmurray, J J V, Solomon, S D, Vaduganathan, M

“…Abstract Background Mechanisms of disease pathobiology, prognosis, and potentially treatment responses might vary by race in patients with heart failure (HF)…”
Get full text

Natriuretic peptides, kidney function and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: pooled data from the I-PRESERVE, TOPCAT, PARAGON and DELIVER trials by Neuen, B L, Vaduganathan, M, Claggett, B L, Beldhuis, I, Myhre, P, Desai, A S, Skali, H, Mccausland, F R, Mcgrath, M, Anand, I, Zile, M R, Pfeffer, M A, Mcmurray, J J V, Solomon, S D

“…Abstract Background The prognostic utility of N-terminal pro-B-type (NT-proBNP) in patients with heart failure and chronic kidney disease (CKD) is incompletely…”
Get full text

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF by Lu, H, Claggett, B L, Packer, M, Lam, C S P, Swedberg, K, Rouleau, J, Zile, M R, Lefkowitz, M, Desai, A S, Jhund, P, Mcmurray, J J V, Solomon, S D, Vaduganathan, M

“…Abstract Background Sacubitril/valsartan is indicated to reduce the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with…”
Get full text

Differences in risk profiles and clinical outcomes according to age in patients with high-risk myocardial infarction: insights from the PARADISE-MI trial by Jering, K, Claggett, B L, Solomon, S D, Cikes, M, Granger, C B, Kober, L, Landmesser, U, Lewis, E F, Maggioni, A P, Mcmurray, J J V, Merkely, B, Opolski, G, Rouleau, J L, Senni, M, Pfeffer, M A

“…Abstract Introduction Temporal declines in rates of rehospitalization and death after acute myocardial infarction (MI) have not been uniform across age groups…”
Get full text

Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial by Neuen, B L, Ostrominski, J W, Claggett, B L, Beldhuis, I, Chatur, S, Arnott, C, Heerspink, H J L, Pollock, C, Jardine, M, Mahaffey, K W, Perkovic, V, Solomon, S D, Vaduganathan, M

“…Abstract Background The extent to which chronic kidney disease (CKD) progression increases cardiovascular risk, and whether different types of cardiovascular…”
Get full text

Prognostic importance of persistent elevations in high-sensitivity troponin T in the early convalescent phase (two weeks) following high-risk myocardial infarction: insights from the PARADISE-MI trial by Jering, K, Claggett, B L, Pfeffer, M A, Amir, O, Barkoudah, E, Kober, L, Maggioni, A M, Mann, D L, Mcmurray, J J V, Mehran, R, Ntsekhe, M, Solomon, S D, Steg, P G, Tokmakova, M, Braunwald, E

“…Abstract Introduction Myocardial infarction (MI) is defined by a rise and fall in cardiac troponin (cTn) with clinical evidence of acute myocardial ischemia…”
Get full text

Obesity and renal impairment in patients with heart failure and reduced ejection fraction: another obesity paradox? by Matsumoto, S, Henderson, A D, Shen, L, Desai, A S, Swedberg, K, Claggett, B L, Lefkowitz, M P, Rouleau, J L, Vaduganathan, M, Packer, M, Zile, M R, Jhund, P S, Solomon, S D, Mcmurray, J J V

“…Abstract Background Obesity is associated with poor cardiovascular outcomes in patients with HF and reduced ejection fraction (HFrEF). However, whether obesity…”
Get full text

Relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine in chronic kidney disease: a secondary analysis of the DANFLU-1 trial by Bartholdy, K, Johansen, N D, Janstrup, K H, Modin, D, Nealon, J, Samson, S, Salamand, C, Loiacono, M M, Jensen, A M R, Landler, N E, Claggett, B L, Solomon, S D, Gislason, G H, Koeber, L, Biering-Soerensen, T

“…Abstract Background Morbidity and mortality from influenza and cardiovascular disease occur frequently in persons with chronic kidney disease (CKD). Limited…”
Get full text

Standardized longitudinal strain curves stratified by age and sex in healthy individuals: The Copenhagen City Heart Study by Christensen, J, Simonsen, J O, Modin, D, Skaarup, K, Lassen, M C H, Johansen, N D, Sanchez-Martinez, S, Claggett, B L, Marott, J L, Jensen, G B, Schnohr, P, Moegelvang, R, Biering-Soerensen, T

“…Abstract Introduction Speckle-tracking echocardiography has gained widespread use, and strain parameters such as global longitudinal strain (GLS) and strain…”
Get full text

Electronic nudge letters to increase influenza vaccination uptake in younger and middle-aged individuals with diabetes: a prespecified analysis of the NUDGE-FLU-CHRONIC trial by Lassen, M C H, Johansen, N D, Vaduganathan, M, Bhatt, A S, Modin, D, Chatur, S, Claggett, B L, Janstrup, K H, Kober, L, Solomon, S D, Sivapalan, P, Jensen, J U S, Martel, C J M, Krause, T G, Biering-Soerensen, T

“…Abstract Background Despite evidence demonstrating that influenza vaccination is associated with reduced risk of adverse cardiovascular events and all-cause…”
Get full text

Increased circumferential deformation predicts cardiac events when left ventricular ejection fraction is normal by Skaarup, K G, Lassen, M C H, Johansen, N D, Olsen, F J, Jensen, G B, Schnohr, P, Shah, A, Claggett, B L, Solomon, S D, Mogelvang, R, Biering-Sorensen, T

“…Abstract Background Recent research suggests that early left ventricular (LV) systolic dysfunction is characterized by compromised longitudinal function and a…”
Get full text

PARADISE-MI – event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40 by Petrie, M, Solomon, S, Claggett, B L, Jering, K, Steg, G, Granger, C, Lewis, E, Kober, L, Mann, D, Rouleau, J L, McMurray, J J, Maggioni, A, Braunwald, E, Pfeffer, M A

“…Abstract Background/Introduction Sacubitril/valsartan was compared to ramipril in patients with acute myocardial infarction in the PARADISE-MI trial. In the…”
Get full text

Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization by Desai, Akshay S., MD, MPH, Claggett, Brian L., PhD, Packer, Milton, MD, Zile, Michael R., MD, Rouleau, Jean L., MD, Swedberg, Karl, MD, Shi, Victor, MD, Lefkowitz, Martin, MD, Starling, Randall, MD, Teerlink, John, MD, McMurray, John J.V., MD, Solomon, Scott D., MD

“…Abstract Background Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. Objectives…”
Get full text

Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial by Peikert, A, Bart, B A, Vardeny, O, Vaduganathan, M, Claggett, B L, Desai, A S, Jhund, P S, Kosiborod, M N, Lam, C S P, Martinez, F A, De Boer, R A, Hernandez, A F, Shah, S J, Mc Murray, J J V, Solomon, S D

“…Abstract Background While beta-blockers are not recommended for the treatment of HFpEF according to the latest ESC and AHA/ACC/HFSA guidelines, these therapies…”
Get full text